Company Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors.
The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.
Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Country | British Virgin Islands |
Founded | 1973 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Ian Walters |
Contact Details
Address: Clarence Thomas Building, P.O. Box 4649 Tortola, VG1110 British Virgin Islands | |
Phone | 203 221 7378 |
Website | portagebiotech.com |
Stock Details
Ticker Symbol | PRTG |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001095435 |
CUSIP Number | G7185A128 |
ISIN Number | VGG7185A1286 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ian B. Walters M.B.A., M.D. | Chief Executive Officer and Chairman of Board |
Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer |
Brian Wiley | Chief Business Officer |
Adam Melero | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 4, 2024 | 424B3 | Prospectus |
Oct 4, 2024 | 6-K | Report of foreign issuer |
Oct 3, 2024 | 144 | Filing |
Sep 27, 2024 | 144 | Filing |
Sep 23, 2024 | 144 | Filing |
Sep 20, 2024 | 144 | Filing |
Sep 4, 2024 | 424B3 | Prospectus |
Sep 4, 2024 | 6-K | Report of foreign issuer |
Aug 27, 2024 | EFFECT | Notice of Effectiveness |
Aug 27, 2024 | 6-K | Report of foreign issuer |